An interventional study of root canal treatment and intracanal medicament and Regeneration in Apical Periodontitis, sponsored by Sara Tariq Elemam. Completed at 1 site in Egypt. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Sara Tariq Elemam · Not applicable, Interventional, and Treatment
A randomized control trial which aim to compare the healing potential for the following treatment options for mature teeth with apical periodontitis:
Group I: Conventional root canal treatment (CRT) Group II: Regenerative endodontic treatment (RET) using a blood clot scaffold Group III: RET using a blood clot scaffold loaded with recombinant human BMPs (rhBMPs)
246 studies on the registry are indexed under Periapical Periodontitis; 64 are open to participants now.
This study's enrollment of 30 is below the median of 60 across 211 interventional studies indexed under Periapical Periodontitis.
Browse Periapical Periodontitis studies →This is the only study on the registry with Sara Tariq Elemam as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Procedure: root canal treatment and intracanal medicament
Procedure: Regeneration with BMPs
Procedure: Regeneration
conventional root canal treatment with obturation
Regeneration using induction of bleeding
RET using a blood clot scaffold loaded with recombinant human BMPs (rhBMPs)
Healing in terms of volumetric change of lesion analyzed by CBCT
Time frame: 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.